Onward Ho! Glenmark Strikes First Onco Asset Deal With China’s Harbour BioMed
Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.
You may also be interested in...
Glenmark has kicked off 2019 with more regional deal-making, sealing an alliance for its investigational rhinitis asset with Yuhan in South Korea. But the outlook for the fixed-dose combination nasal spray also hinges on its US approval.
2018 has seen some interesting Indo-Chinese pharma linkages amid evolving regulations in China and generally improved overall ties between the Asian neighbors. Could the trend stick in 2019 with more Indian firms taking a shot at the world’s second-largest pharma market?
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.